90Y Radioembolization for Locally Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Long-Term Outcomes in a 185-Patient Cohort
- PMID: 29217739
- DOI: 10.2967/jnumed.117.199752
90Y Radioembolization for Locally Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Long-Term Outcomes in a 185-Patient Cohort
Abstract
We report survival outcomes for patients with advanced-stage hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) treated with 90Y radioembolization. Methods: With institutional review board approval, we searched our prospectively acquired database for 90Y patients treated between 2003 and 2017. Inclusion criteria were patients who had HCC with tumor PVT. Patients with metastases were excluded. Laboratory data were collected at baseline and 1 mo after 90Y radioembolization. Toxicity grades were reported according to the Common Terminology Criteria for Adverse Events, version 4.0, and long-term survival outcomes were reported and stratified by Child-Pugh class (CP). Overall survival was calculated using the Kaplan-Meier method. Multivariate analysis was performed using Cox proportional hazards regression. A subanalysis for patients with a high level of α-fetoprotein (AFP) (>100 ng/dL) was conducted. Results: In total, 185 patients with HCC PVT underwent 90Y radioembolization. Seventy-four (40%) were CP-A, 51 (28%) were CP-B7, and 60 (32%) were ≥CP-B8. New albumin, bilirubin, and alkaline phosphatase grade 3/4 toxicities were, respectively, 3%, 10%, and 0% for CP-A; 14%, 12%, and 6% for CP-B7; and 23%, 32%, and 3% for ≥CP-B8. Median overall survival for CP-A patients was 13.3 mo (95% confidence interval [CI], 8.7-15.7 mo). CP-B7 and ≥CP-B8 patients exhibited median overall survival of 6.9 mo (95% CI, 5.3-10.1 mo) and 3.9 mo (95% CI, 2.9-5.0 mo), respectively. Significant overall survival prognosticators on univariate analysis were albumin, bilirubin, ascites, tumor size 5 cm or smaller, focality, distribution, infiltration, Eastern Cooperative Oncology Group status, AFP level, and PVT extent. Multivariate analysis showed the prognosticators of overall survival to be bilirubin, no ascites, tumor size 5 cm or smaller, solitary lesion, baseline AFP level lower than 100 ng/dL, and Eastern Cooperative Oncology Group status. Of 123 patients with a high AFP level (>100 ng/dL), 12 patients achieved restored normal AFP levels (<13 ng/dL) and exhibited median overall survival of 23.9 mo (95% CI, 20.1-124.1 mo). AFP responders at 1 mo had better overall survival than nonresponders, at 8.5 mo versus 4.8 mo (P = 0.018); AFP responders at 3 mo had overall survival of 13.3 mo, versus 6.9 mo for nonresponders (P = 0.021). Conclusion:90Y radioembolization can serve as a safe and effective treatment for advanced-stage HCC patients with tumor PVT. Overall survival outcomes are affected by baseline liver function, tumor size, and AFP level.
Keywords: 90Y radioembolization; hepatocellular carcinoma (HCC); portal vein thrombosis (PVT).
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.
Similar articles
-
Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.J Vasc Interv Radiol. 2016 Jun;27(6):812-821.e2. doi: 10.1016/j.jvir.2016.01.147. Epub 2016 Apr 7. J Vasc Interv Radiol. 2016. PMID: 27062356
-
Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.Cancer. 2015 Jul 1;121(13):2164-74. doi: 10.1002/cncr.29275. Epub 2015 Apr 6. Cancer. 2015. PMID: 25847227 Clinical Trial.
-
Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.Cancer Biother Radiopharm. 2015 Apr;30(3):132-8. doi: 10.1089/cbr.2014.1748. Epub 2015 Mar 11. Cancer Biother Radiopharm. 2015. PMID: 25760644
-
A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis.Saudi J Gastroenterol. 2016 Sep-Oct;22(5):353-359. doi: 10.4103/1319-3767.191139. Saudi J Gastroenterol. 2016. PMID: 27748320 Free PMC article. Review.
-
Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses.Oncotarget. 2016 Nov 1;7(44):72343-72355. doi: 10.18632/oncotarget.11644. Oncotarget. 2016. PMID: 27579537 Free PMC article. Review.
Cited by
-
Transplant and non-transplant HCC patients at a single institution.Hepatol Forum. 2024 Feb 12;5(2):77-86. doi: 10.14744/hf.2023.2023.0057. eCollection 2024. Hepatol Forum. 2024. PMID: 38487742 Free PMC article.
-
Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape.Cancers (Basel). 2024 Feb 4;16(3):666. doi: 10.3390/cancers16030666. Cancers (Basel). 2024. PMID: 38339417 Free PMC article. Review.
-
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma.Oncologist. 2024 Mar 4;29(3):270-e413. doi: 10.1093/oncolo/oyad331. Oncologist. 2024. PMID: 38325328 Free PMC article. Clinical Trial.
-
Transarterial Radioembolization for Management of Hepatocellular Carcinoma.Oncologist. 2024 Feb 2;29(2):117-122. doi: 10.1093/oncolo/oyad327. Oncologist. 2024. PMID: 38128565 Free PMC article.
-
Multidisciplinary Taiwan consensus for the use of conventional TACE in hepatocellular carcinoma treatment.Front Oncol. 2023 Jun 20;13:1186674. doi: 10.3389/fonc.2023.1186674. eCollection 2023. Front Oncol. 2023. PMID: 37427137 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous